Developments in the Management of Myelofibrosis After ASH 2024

Sangeetha Venugopal, MD, MS, discusses treatment trends and emerging data in the management of myelofibrosis.

EP. 1: Treatment Trends: JAK Inhibitor Selection in Myelofibrosis

December 20th 2024

Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.

EP. 2: Challenges With Low-Dose Ruxolitinib in Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses challenges with low-dose ruxolitinib in myelofibrosis.

EP. 3: The Relationship Between Thrombocytopenia/Anemia on Disease Progression in Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses the relationship between thrombocytopenia and anemia on disease progression in myelofibrosis

EP. 4: PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses post hoc overall survival data for pacritinib in myelofibrosis.

EP. 5: Data for Navtemadlin in Relapsed/Refractory Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

EP. 6: Other Notable Myelofibrosis Data From ASH 2024

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses other notable myelofibrosis data from the 2024 ASH Annual Meeting.